114 related articles for article (PubMed ID: 21653768)
21. Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group.
Bale MJ; Jones RN
J Clin Microbiol; 1993 Sep; 31(9):2538-40. PubMed ID: 8408586
[TBL] [Abstract][Full Text] [Related]
22. Agar disk diffusion (Bauer-Kirby) tests with various fastidious and nonfastidious reference (ATCC) strains: comparison of several agar media.
Traub WH; Leonhard B
Chemotherapy; 1994; 40(6):374-83. PubMed ID: 7842820
[TBL] [Abstract][Full Text] [Related]
23. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Anderegg TR; Biedenbach DJ; Jones RN;
Diagn Microbiol Infect Dis; 2003 Jun; 46(2):147-50. PubMed ID: 12812719
[TBL] [Abstract][Full Text] [Related]
24. Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.
Ross JE; Mendes RE; Jones RN
J Clin Microbiol; 2014 Sep; 52(9):3399-401. PubMed ID: 24920777
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility testing quality control studies with fosfomycin tromethamine.
Fuchs PC; Barry AL; Brown SD
Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):538-40. PubMed ID: 9272392
[TBL] [Abstract][Full Text] [Related]
26. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.
Fuchs PC; Jones RN; Barry AL; Gavan TL
J Clin Microbiol; 1989 Jan; 27(1):49-52. PubMed ID: 2492304
[TBL] [Abstract][Full Text] [Related]
27. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2010)].
Goto H; Iwasaki M
Jpn J Antibiot; 2015 Apr; 68(2):85-104. PubMed ID: 26182813
[TBL] [Abstract][Full Text] [Related]
28. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
Anderegg TR; Jones RN;
Diagn Microbiol Infect Dis; 2003 Jan; 45(1):73-6. PubMed ID: 12573554
[TBL] [Abstract][Full Text] [Related]
29. Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.
Jones RN; Barry AL
J Clin Microbiol; 1987 Nov; 25(11):2211-3. PubMed ID: 3121667
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.
Jones RN; Fritsche TR; Sader HS
Antimicrob Agents Chemother; 2008 Oct; 52(10):3763-75. PubMed ID: 18573936
[TBL] [Abstract][Full Text] [Related]
31. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
32. Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity.
Traczewski MM; Ambler JE; Schuch R
J Clin Microbiol; 2021 Jun; 59(7):e0311720. PubMed ID: 33910968
[TBL] [Abstract][Full Text] [Related]
33. Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.
Riedel S; Ross JE; Farrell DJ; Flamm RK; Jones RN
J Clin Microbiol; 2015 Dec; 53(12):3888-90. PubMed ID: 26378286
[TBL] [Abstract][Full Text] [Related]
34. Analysis of a single reference strain for determination of gentamicin regression line constants and inhibition zone diameter breakpoints in quality control of disk diffusion antibiotic susceptibility testing.
Kronvall G
J Clin Microbiol; 1982 Nov; 16(5):784-93. PubMed ID: 6818249
[TBL] [Abstract][Full Text] [Related]
35. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2011)].
Goto H; Iwasaki M
Jpn J Antibiot; 2015 Apr; 68(2):105-24. PubMed ID: 26182814
[TBL] [Abstract][Full Text] [Related]
36. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2008)].
Goto H; Iwasaki M
Jpn J Antibiot; 2015 Feb; 68(1):19-36. PubMed ID: 25980051
[TBL] [Abstract][Full Text] [Related]
37. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Jones RN; Kugler KC; Erwin ME; Biedenbach DJ; Beach ML; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):247-53. PubMed ID: 10212751
[TBL] [Abstract][Full Text] [Related]
38. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2007)].
Goto H; Iwasaki M
Jpn J Antibiot; 2015 Feb; 68(1):1-18. PubMed ID: 25980050
[TBL] [Abstract][Full Text] [Related]
39. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.
Barry AL; Thornsberry C; Gavan TL
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865
[TBL] [Abstract][Full Text] [Related]
40. N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluation.
Asadipour A; Moshafi MH; Khosravani L; Moghimi S; Amou E; Firoozpour L; Ilbeigi G; Beiki K; Soleimani E; Foroumadi A
Daru; 2018 Dec; 26(2):199-207. PubMed ID: 30392156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
